» Articles » PMID: 946508

Clinical Experience with Theophylline. Relarionships Between Dosage, Serum Concentration, and Toxicity

Overview
Journal JAMA
Specialty General Medicine
Date 1976 May 3
PMID 946508
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Relationships between theophylline dosage, serum theophylline concentration, and theophylline toxicity were evaluated retrospectively in 47 hospitalized adults. The amount of theophylline administered daily varied more than sixfold, from 6 to 38 mg/kg. The serum theophylline concentrations, however, varied 24-fold from 2 to 49 mug/ml. The relationship between daily dosage and serum concentration was unpredictable in an individual patient. Fourteen patients (30%) had a toxic reaction to theophylline. Toxic symptoms, which were not always gastrointestinal, occurred commonly with serum concentrations over 25 mug/ml but were not noted with concentrations below 15 mug/ml. High serum theophylline concentrations and a toxic reaction developed just as often with the oral route as when the drug was given intravenously. In six patients, measurement of serum theophylline concentration disclosed subtherapeutic concentrations. Serum theophylline determination appears to be important clinically in guiding effective and safe usage of theophylline.

Citing Articles

Current status and usefulness of therapeutic drug monitoring implementation of theophylline in elderly patients based on a nationwide database study and modeling approach.

Okada A, Sera S, Taguchi M, Yamada H, Nagai N Sci Prog. 2024; 107(3):368504241285122.

PMID: 39311625 PMC: 11425750. DOI: 10.1177/00368504241285122.


Smart chemometrics-assisted spectrophotometric methods for efficient resolution and simultaneous determination of paracetamol, caffeine, drotaverine HCl along with three of their corresponding related impurities.

Tawfik S, Hegazy M, El-Ragehy N, Sedik G BMC Chem. 2023; 17(1):133.

PMID: 37798793 PMC: 10557158. DOI: 10.1186/s13065-023-01036-8.


acting aptazyme for conditional gene knockdown in eukaryotic cells.

Zhou S, Chen M, Yuan Y, Xu Y, Pu Q, Ai X Mol Ther Nucleic Acids. 2023; 33:367-375.

PMID: 37547296 PMC: 10400872. DOI: 10.1016/j.omtn.2023.07.014.


Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis.

Yang X, Xu Z, Hu S, Shen J Front Pharmacol. 2023; 14:1111393.

PMID: 36865908 PMC: 9973527. DOI: 10.3389/fphar.2023.1111393.


Modulating myoblast differentiation with RNA-based controllers.

Dykstra P, Rando T, Smolke C PLoS One. 2022; 17(9):e0275298.

PMID: 36166456 PMC: 9514614. DOI: 10.1371/journal.pone.0275298.